Australia's most trusted source of pharma news
Earlier
PBS still shrinking, July data shows
Posted 28 August 2017
The PBS recovered slightly in July with outlays rising to $4.42 billion compared with June, although year-on-year the scheme continues to shrink.
PBS pre-rebate expenditure rose 0.5 per cent in July to reach $4.42 billion, but this was almost two per cent less than was paid out in July 2016.
The hepatitis C drugs continue to exert their dominance over the scheme, with Gilead's Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) topping the table as the highest earning drugs, followed by BMS' Daklinza (daclatasvir).
Growth of Sovaldi and Daklinza is fast-outstripping that of Harvoni, although together the Gilead pair pull in more than a fifth of all PBS income.
With growth of more than 900 per cent, Gilead's once-a-day HIV pill offering Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is now the third biggest earner for Gilead, showing promise for the company outside the HCV market.
Gilead and BMS continue to enjoy strong growth on the back of their HCV offerings, with both companies experiencing 77 per cent PBS pre-rebate income growth in the year to July 2017.
BMS made $582.2 million in the past 12 months while MSD is also experiencing strong growth of 29 per cent on the back of its PD-L1 inhibitor Keytruda (pembrolizumab), which climbed to 12th place on the list of highest-earning brands with income of $127.4 million.
Outside the HCV antivirals, Keytruda is the fastest growing drug. In comparison, rival PD-1 inhibitor Opdivo (nivolumab), which dominates the market checkpoint inhibitor market globally, has struggled to gain traction locally. While growing fast, its PBS pre-rebate earnings were just $9 million.
BMS's blood thinner Eliquis (apixaban), which is also slowing clawing its way up through the ranks, is having more success with its annual income approaching $93 million.
Bayer and AstraZeneca both experienced growth of between 10 and 11 per cent in the past 12 months with Bayer's Eylea (aflibercept) continuing to perform well for the company in the wet AMD market, clearly eating competitor Novartis' Lucentis (ranibizumab) market share.
Eylea grew by 15 per cent while Lucentis' income shrunk by 11.4 per cent.
Amgen's Prolia (denosumab) is growing strongly, its income up 26 per cent in 12 months to $120.2 million while Astellas' prostate cancer drug Xtandi (enzalutamide) enjoyed a 28 per cent jump in PBS pre-rebate income to $70 million.
Pfizer's Lyrica (pregabalin), enjoying its last month of PBS exclusivity, brought in almost $155 million for Pfizer, a growth of 11 per cent over the 12 months. Overall, Pfizer's PBS income jumped 9.5 per cent with rheumatoid arthritis immunotherapy Xeljanz (tofacitinib) growing 132 per cent to $46 million.
Merck Serono has rapidly declining PBS income, dropping 13 per cent in 12 months to $109 million while Novo Nordisk is also suffering declining income, down three per cent to $135.4 million.
Megan Brodie
megan.brodie@lushmedia.com.au
Analytics for this story were generated using MiPortal, Mercurial's cloud-based business intelligence & analytics platform, Click here for a free trial or contact Regan McCracken on 02 8459 5244. The analysis is based on PBS date of processing data as supplied by the Department of Human Services.
Posted 28 August 2017
The PBS recovered slightly in July with outlays rising to $4.42 billion compared with June, although year-on-year the scheme continues to shrink.
PBS pre-rebate expenditure rose 0.5 per cent in July to reach $4.42 billion, but this was almost two per cent less than was paid out in July 2016.
The hepatitis C drugs continue to exert their dominance over the scheme, with Gilead's Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) topping the table as the highest earning drugs, followed by BMS' Daklinza (daclatasvir).
Growth of Sovaldi and Daklinza is fast-outstripping that of Harvoni, although together the Gilead pair pull in more than a fifth of all PBS income.
With growth of more than 900 per cent, Gilead's once-a-day HIV pill offering Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is now the third biggest earner for Gilead, showing promise for the company outside the HCV market.
Gilead and BMS continue to enjoy strong growth on the back of their HCV offerings, with both companies experiencing 77 per cent PBS pre-rebate income growth in the year to July 2017.
BMS made $582.2 million in the past 12 months while MSD is also experiencing strong growth of 29 per cent on the back of its PD-L1 inhibitor Keytruda (pembrolizumab), which climbed to 12th place on the list of highest-earning brands with income of $127.4 million.
Outside the HCV antivirals, Keytruda is the fastest growing drug. In comparison, rival PD-1 inhibitor Opdivo (nivolumab), which dominates the market checkpoint inhibitor market globally, has struggled to gain traction locally. While growing fast, its PBS pre-rebate earnings were just $9 million.
BMS's blood thinner Eliquis (apixaban), which is also slowing clawing its way up through the ranks, is having more success with its annual income approaching $93 million.
Bayer and AstraZeneca both experienced growth of between 10 and 11 per cent in the past 12 months with Bayer's Eylea (aflibercept) continuing to perform well for the company in the wet AMD market, clearly eating competitor Novartis' Lucentis (ranibizumab) market share.
Eylea grew by 15 per cent while Lucentis' income shrunk by 11.4 per cent.
Amgen's Prolia (denosumab) is growing strongly, its income up 26 per cent in 12 months to $120.2 million while Astellas' prostate cancer drug Xtandi (enzalutamide) enjoyed a 28 per cent jump in PBS pre-rebate income to $70 million.
Pfizer's Lyrica (pregabalin), enjoying its last month of PBS exclusivity, brought in almost $155 million for Pfizer, a growth of 11 per cent over the 12 months. Overall, Pfizer's PBS income jumped 9.5 per cent with rheumatoid arthritis immunotherapy Xeljanz (tofacitinib) growing 132 per cent to $46 million.
Merck Serono has rapidly declining PBS income, dropping 13 per cent in 12 months to $109 million while Novo Nordisk is also suffering declining income, down three per cent to $135.4 million.
Megan Brodie
megan.brodie@lushmedia.com.au
Analytics for this story were generated using MiPortal, Mercurial's cloud-based business intelligence & analytics platform, Click here for a free trial or contact Regan McCracken on 02 8459 5244. The analysis is based on PBS date of processing data as supplied by the Department of Human Services.
Drought, fire and now virus cut chance of PBS relief.
Don't do it for the accolades; do it for your kids.
New forms of rotavirus vaccine Rotarix.